SCHEMBL2284522

SCHEMBL2284522

COC(=O)CNC(=O)c1ccc(/C=C/C(=O)c2c(O)cc(C)[nH]c2=O)cc1

nearest known ligand 0.58

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.50
HTT P42858 4/20 0.50
SMN1; SMN2 Q16637 4/20 0.50
NPSR1 Q6W5P4 2/20 0.50
APP P05067 4/20 0.44
MAPT P10636 1/20 0.43
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
KDM4E B2RXH2 2/20 0.42
TSHR P16473 1/20 0.42
HSD17B10 Q99714 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.41
SLC5A1 P13866 2/20 0.41
SLC5A2 P31639 2/20 0.41
CYP1A2 P05177 1/20 0.41
CYP2C19 P33261 1/20 0.41
MKNK2 Q9HBH9 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2284527 1.00 LMNA (0.50) LMNAHTTSMN1; SMN2NPSR1APP
SCHEMBL2278854 0.90 LMNA (0.52) LMNAHTTSMN1; SMN2NPSR1APP
SCHEMBL2278850 0.90 LMNA (0.52) LMNAHTTSMN1; SMN2NPSR1APP
SCHEMBL2275114 0.89 LMNA (0.43) LMNAHTTSMN1; SMN2NPSR1MAPT
SCHEMBL2275109 0.89 LMNA (0.43) LMNAHTTSMN1; SMN2NPSR1MAPT
SCHEMBL2274871 0.88 LMNA (0.50) LMNAHTTSMN1; SMN2NPSR1APP
SCHEMBL2274875 0.88 LMNA (0.50) LMNAHTTSMN1; SMN2NPSR1APP
SCHEMBL2277293 0.83 APP (0.43) SMN1; SMN2APPMEN1KMT2AKDM4E
SCHEMBL2277289 0.83 APP (0.43) SMN1; SMN2APPMEN1KMT2AKDM4E
SCHEMBL2279822 0.81 LMNA (0.52) LMNAHTTSMN1; SMN2NPSR1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7989478-B2 decreases expression of a Type I collage gene in a tissue to induce a reduction in accumulation of collagen and thereby improves tissue fibrosis SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-08-02 US disclosed
US-7989478-B2 decreases expression of a Type I collage gene in a tissue to induce a reduction in accumulation of collagen and thereby improves tissue fibrosis SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-08-02 US disclosed
US-7989478-B2 decreases expression of a Type I collage gene in a tissue to induce a reduction in accumulation of collagen and thereby improves tissue fibrosis SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-08-02 US disclosed
US-20060211680-A1 decreases expression of a Type I collage gene in a tissue to induce a reduction in accumulation of collagen and thereby improves tissue fibrosis SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2006-09-21 US disclosed
EP-1671948-A1 CINNAMOYL COMPOUND AND USE OF THE SAME Sumitomo Chemical Company, Limited (JP) 2006-06-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060211680-A1 decreases expression of a Type I collage gene in a tissue to induce a reduction in accumulation of collagen and thereby improves tissue fibrosis COL2A1, COL1A1, COL14A1 LMNA 537/4885HTT 4798/4885SMN1; SMN2 3766/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.